CSL Ltd
ASX:CSL
CSL Ltd
ASX:CSL
Price:
275.8 AUD
0.15%
Market Closed
Updated:
May 5, 2024
CSL Ltd
Operating Income
|
CSL Ltd
Operating Income Peer Comparison
Comparables:
IMM
MSB
CUV
TLX
PYC
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$3.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Immutep Ltd
ASX:IMM
|
Operating Income
-AU$46.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-13%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$55.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Operating Income
AU$50.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$17.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$21.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-17%
|
See Also
What is CSL Ltd's Operating Income?
Operating Income
3.7B
USD
3.7B
USD
Based on the financial report for Dec 31, 2023, CSL Ltd's Operating Income amounts to 3.7B USD.
What is CSL Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
9%
9%
Over the last year, the Operating Income growth was 25%. The average annual Operating Income growth rates for CSL Ltd have been 2% over the past three years , 8% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
